Show simple item record

dc.contributor.authorNieder, Carsten
dc.contributor.authorAndratschke, Nicolaus H.
dc.contributor.authorGrosu, Anca L.
dc.date.accessioned2023-08-10T10:42:24Z
dc.date.available2023-08-10T10:42:24Z
dc.date.issued2023-04-11
dc.description.abstractBackground and objectives: The validated LabBM score (laboratory parameters in patients with brain metastases) represents a widely applicable survival prediction model, which incorporates 5 blood test results (serum lactate dehydrogenase (LDH), C-reactive protein (CRP), albumin, platelets and hemoglobin). All tests are classified as normal or abnormal, without accounting for the wide range of abnormality observed in practice. We tested the hypothesis that improved stratification might be possible, if more granular test results are employed.<p> <p>Methods: Retrospective analysis of 198 patients managed with primary whole-brain radiotherapy in one of the institutions who validated the original LabBM score.<p> <p>Results: For two blood tests (albumin, CRP), discrimination was best for the original dichotomized version (normal/abnormal). For two others (LDH, hemoglobin), a three-tiered classification was best. The number of patients with low platelet count was not large enough for detailed analyses. A modified LabBM score was developed, which separates the intermediate of originally 3 prognostic groups into 2 statistically significantly different strata, resulting in a 4-tiered score.<p> <p>Conclusion: This initial proof-of-principle study suggests that granular blood test results might contribute to further improvement of the score, or alternatively development of a nomogram, if additional large-scale studies confirm the encouraging results of the present analysis.en_US
dc.identifier.citationNieder, Andratschke, Grosu. Personalized radiotherapy of brain metastases: survival prediction by means of dichotomized or differentiated blood test results?. Frontiers in Oncology. 2023;13en_US
dc.identifier.cristinIDFRIDAID 2155825
dc.identifier.doi10.3389/fonc.2023.1156161
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/10037/29849
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.relation.journalFrontiers in Oncology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0en_US
dc.rightsAttribution 4.0 International (CC BY 4.0)en_US
dc.titlePersonalized radiotherapy of brain metastases: survival prediction by means of dichotomized or differentiated blood test results?en_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

Attribution 4.0 International (CC BY 4.0)
Except where otherwise noted, this item's license is described as Attribution 4.0 International (CC BY 4.0)